BioMedNewsBreaks

WednesdayApr 01, 2026 10:44 am

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year 

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology. To view the full press release, visit https://ibn.fm/YF5Vl About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech…

Continue Reading

TuesdayMar 31, 2026 2:50 pm

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) ‘Significant Turning Point’ Spotlighted in Recent Article

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. The piece reads, “‘We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection,’ the February 2026 report states. The report highlights a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment,…

Continue Reading

TuesdayMar 31, 2026 9:30 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide in Behçet’s Disease, ongoing development of SGX302 and SGX945 programs and a year-end cash position of approximately $7.9 million, as it continues to pursue strategic options to support late-stage development. To view the full press release, visit https://ibn.fm/b1p2y About Soligenix Soligenix is a late-stage…

Continue Reading

TuesdayMar 31, 2026 9:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Selects Global Brand Name Candidate for AVERSA(TM) Fentanyl Patch

Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA(TM) technology, could become the first abuse-deterrent fentanyl patch designed to reduce misuse and accidental exposure, targeting a potential peak annual U.S. market of $80 million to $200 million while addressing broader global pain management needs. To view the full press release, visit https://ibn.fm/QBBSF About Nutriband Inc. We are primarily engaged in the…

Continue Reading

TuesdayMar 31, 2026 9:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View

Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now targets an estimated annual market opportunity of more than $15 billion, while its RADR(R) platform and newly introduced withZeta.ai multi-agentic co-scientist platform are expanding commercial potential, with beta testing underway at more than 25 biotech companies, cancer research centers and biopharma consultants, as Lantern ended…

Continue Reading

ThursdayMar 26, 2026 12:22 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation from the European Medicines Agency and supportive Phase 2a data demonstrating biological efficacy and safety. The designation provides up to 10 years of market exclusivity in the European Union and adds to existing FDA orphan and fast track designations, as the company advances its innate defense regulator platform targeting unmet needs in rare autoimmune conditions. To view the full press release, visit https://ibn.fm/847sO About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical…

Continue Reading

TuesdayMar 24, 2026 11:03 am

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Launches MyOnlineConsultation Platform Through MOCTeledoc 

Earth Science Tech (OTC: ETST) announced the official launch of MyOnlineConsultation.com through MOCTeledoc LLC, a fully integrated doctor network providing technology and clinical staffing solutions to digital health companies, following a beta phase that achieved cash-flow-positive status. The platform supports ETST’s vertically integrated healthcare ecosystem by connecting its prescriber network with compounding pharmacies, including RxCompound and Mister Meds, while offering turnkey telehealth technology, clinical staffing and integrated fulfillment as the company positions MOCTeledoc as a new revenue stream alongside divisions that generated $25.9 million for the nine months ended Dec. 31, 2025. To view the full press release, visit https://ibn.fm/Zc1QQ About Earth Science Tech, Inc. (ETST) Earth Science…

Continue Reading

TuesdayMar 24, 2026 10:55 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 million, down from $18.5 million in 2024, alongside lower research and development and general and administrative expenses, and ended the year with approximately $7.8 million in cash, which management believes will support operations through the end of 2026. To view the full press release, visit https://ibn.fm/KQHm4…

Continue Reading

TuesdayMar 24, 2026 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM) nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The company will highlight its next-generation drug delivery technology along with two lead candidates, Sapu003 (Everolimus for Injection), currently in Phase 1 trials, and Sapu006 (Docetaxel for Injection), entering Phase 1, as it seeks strategic partnerships to advance development and commercialization. To view the full press release, visit https://ibn.fm/Slq47 About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug…

Continue Reading

TuesdayMar 24, 2026 9:20 am

BioMedNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Advances Anti-Drone Capabilities Through AFD Deployment Of Anduril Lattice Platform

Gaxos.ai (NASDAQ: GXAI) announced that its portfolio company, America First Defense (AFD), has begun deployment of the Anduril Lattice Platform to expand its counter-swarm UAV and anti-drone defense systems, marking a key milestone in advancing its autonomous defense infrastructure. The integration enhances AFD’s ability to identify, track, assess and respond to evolving unmanned aerial threats, supporting its focus on layered, AI-enabled counter-UAS solutions as demand grows for adaptive, software-defined defense technologies. To view the full press release, visit https://ibn.fm/KoGYn About Gaxos.ai Inc. Gaxos.AI is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life…

Continue Reading